-
DTC常见的远处转移部位是肺、骨、脑、肝、肾和皮肤等,其中以肺转移最为常见。多数DTC肺转移患者经规范化综合治疗后可达到部分或完全缓解,然而部分患者由于发现较晚、治疗不规范或出现碘难治性状态,导致其生存质量变差,生存率明显降低。因此,DTC肺转移已成为临床研究的热点和重点,笔者就DTC肺转移的研究进展综述如下。
分化型甲状腺癌肺转移的研究进展
Research progress in pulmonary metastasis of differentiated thyroid cancer
-
摘要: 分化型甲状腺癌(DTC)的发病率呈逐年上升趋势,当发生远处转移时患者的生存质量变差、生存率明显降低。肺是DTC最常见的远处转移部位,占DTC远处转移的55%~85%。DTC肺转移是造成甲状腺癌患者病死的主要因素。故针对此类患者的早期诊断、评估以及治疗决策的制定尤为重要,同时这也是缩短我国与发达国家甲状腺癌诊治的差距、提高患者生存质量的关键。笔者就近年来有关DTC肺转移的流行病学及临床病理特征、诊断与动态评估以及治疗方法等研究进展作一综述。Abstract: The incidence of differentiated thyroid carcer (DTC) is increasing year by year. When distant metastasis occurs, the patients' life quality and survival rate were significantly reduced. Lung is the most common site, accounting for 55%-85% of distant metastasis with DTC, and is the main factor of death threat of thyroid cancer. Therefore, early diagnosis, evaluation and treatment decisions for these patients are particularly important, and it is also the key to shorten the gap between the diagnosis and treatment of thyroid cancer in China and developed countries and improve the quality of life of patients. This paper reviews the research progress in the epidemiological and clinic pathologic features, diagnosis, evaluation and treatment of pulmonary metastasis with DTC.
-
Key words:
- Thyroid neoplasms /
- Neoplasm metastasis /
- Pulmonary metastasis
-
[1] Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1−133. DOI: 10.1089/thy.2015.0020. [2] Sohn SY, Kim HI, Kim YN, et al. Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up[J]. Clin Endocrinol, 2018, 88(2): 318−326. DOI: 10.1111/cen.13489. [3] Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy[J]. J Clin Endocrinol Metab, 2006, 91(8): 2892−2899. DOI: 10.1210/jc.2005-2838. [4] Hirsch D, Levy S, Tsvetov G, et al. Long-term outcomes and prognostic factors in patients with differentiated thyroid cancer and distant metastases[J]. Endocr Pract, 2017, 23(10): 1193−1200. DOI: 10.4158/EP171924.OR. [5] Rehman S, Dhatariya KK. Metastatic hürthle cell carcinoma presenting with low free thyroxine, severe hypercalcemia and spurious growth hormone production[J/OL]. AACE Clin Case Rep, 2019, 5(3): e204−e209[2021-04-26]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876938/. DOI: 10.4158/ACCR-2018-0440. [6] 李娜, 邸玉青, 高洪波, 等. 儿童分化型甲状腺癌肺转移14例131I治疗分析[J]. 临床儿科杂志, 2020, 38(9): 651−654. DOI: 10.3969/j.issn.1000-3606.2020.09.003.
Li N, Di YQ, Gao HB, et al. Analysis of 131I therapy of pulmonary metastasis in differentiated thyroid cancer in 14 children[J]. J Clin Pediatr, 2020, 38(9): 651−654. DOI: 10.3969/j.issn.1000-3606.2020.09.003.[7] Zhao T, Liang J, Li T, et al. Serial stimulated thyroglobulin measurements are more specific for detecting distant metastatic differentiated thyroid cancer before radioiodine therapy[J]. Chin J Cancer Res, 2017, 29(3): 213−222. DOI: 10.21147/j.issn.1000-9604.2017.03.07. [8] 李成乾, 王国强, 王叙馥, 等. 首次131I治疗前刺激性Tg对分化型甲状腺癌转移的预测价值[J]. 中华核医学与分子影像杂志, 2019, 39(7): 395−399. DOI: 10.3760/cma.j.issn.2095-2848.2019.07.003.
Li CQ, Wang GQ, Wang XF, et al. Predictive value of stimulated thyroglobulin for metastases from differentiated thyroid carcinoma before the first 131I treatment[J]. Chin J Nucl Med Mol Imaging, 2019, 39(7): 395−399. DOI: 10.3760/cma.j.issn.2095-2848.2019.07.003.[9] Couto JS, Almeida MFO, Trindade VCG, et al. A cutoff thyroglobulin value suggestive of distant metastases in differentiated thyroid cancer patients[J/OL]. Braz J Med Biol Res, 2020, 53(11): e9781[2021-04-26]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561073/. DOI: 10.1590/1414-431X20209781. [10] Ito Y, Onoda N, Kihara M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in differentiated thyroid carcinoma having distant metastasis: a comparison with thyroglobulin-doubling rate and tumor volume-doubling rate[J]. In Vivo, 2021, 35(2): 1125−1132. DOI: 10.21873/invivo.12358. [11] Song HJ, Qiu ZL, Shen CT, et al. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors[J]. Eur J Endocrinol, 2015, 173(3): 399−408. DOI: 10.1530/EJE-15-0296. [12] Kim M, Kim WG, Park S, et al. Initial size of metastatic lesions is best prognostic factor in patients with metastatic differentiated thyroid carcinoma confined to the lung[J]. Thyroid, 2017, 27(1): 49−58. DOI: 10.1089/thy.2016.0347. [13] Song EY, Ahn J, Jeon MJ, et al. Estimating the growth rate of lung metastases in differentiated thyroid carcinoma: response evaluation criteria in solid tumors or doubling time?[J]. Thyroid, 2020, 30(3): 418−424. DOI: 10.1089/thy.2019.0341. [14] 李亚, 左书耀, 孔艳, 等. 131I全身显像与CT及X线胸片对分化型甲状腺癌肺转移诊断价值[J]. 齐鲁医学杂志, 2015, 30(4): 455−456. DOI: 10.13362/j.qlyx.201504026.
Li Y, Zuo SY, Kong Y, et al. Diagnostic value of 131I-WBI, CT and chest X-ray for differentiated thyroid cancer with pulmonary metastasis[J]. Med J Qilu, 2015, 30(4): 455−456. DOI: 10.13362/j.qlyx.201504026.[15] Okuyucu K, Ince S, Alagoz E, et al. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging 18F-FDG PET/CT[J]. Hell J Nucl Med, 2016, 19(3): 208−217. DOI: 10.1967/s002449910402. [16] Maruoka Y, Baba S, Isoda T, et al. Association between volumetric analysis of lung metastases on F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography and short-term progression after I-131 therapy for differentiated thyroid carcinoma[J]. Indian J Nucl Med, 2017, 32(3): 167−172. DOI: 10.4103/ijnm.IJNM_43_17. [17] Yang X, Li J, Li XY, et al. TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer[J]. J Nucl Med, 2017, 58(2): 258−265. DOI: 10.2967/jnumed.116.180240. [18] Porterfield JR, Cassivi SD, Wigle DA, et al. Thoracic metastasectomy for thyroid malignancies[J]. Eur J Cardiothorac Surg, 2009, 36(1): 155−158. DOI: 10.1016/j.ejcts.2008.12.055. [19] Moneke I, Kaifi JT, Kloeser R, et al. Pulmonary metastasectomy for thyroid cancer as salvage therapy for radioactive iodine-refractory metastases[J]. Eur J Cardiothorac Surg, 2018, 53(3): 625−630. DOI: 10.1093/ejcts/ezx367. [20] Verburg FA, Hänscheid H, Luster M. Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer[J]. Best Pract Res Clin Endocrinol Metab, 2017, 31(3): 279−290. DOI: 10.1016/j.beem.2017.04.010. [21] Chen P, Feng HJ, Ouyang W, et al. Risk factors for nonremission and progression-free survival after I-131 therapy in patients with lung metastasis from differentiated thyroid cancer: a single-institute, retrospective analysis in southern china[J]. Endocr Pract, 2016, 22(9): 1048−1056. DOI: 10.4158/EP151139.OR. [22] Gietka-Czernel M, Hubalewska-Dydejczyk A, Kos-Kudła B, et al. Expert opinion on liquid L-thyroxine usage in hypothyroid patients and new liquid thyroxine formulation-Tirosint SOL [opinia ekspertów dotycząca stosowania płynnej postaci lewotyroksyny oraz nowego preparatu Tirosint SOL u chorych na niedoczynność tarczycy][J]. Endokrynol Pol, 2020, 71(5): 441−465. DOI: 10.5603/EP.a2020.0065. [23] Carhill AA, Litofsky DR, Ross DS, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012[J]. J Clin Endocrinol Metab, 2015, 100(9): 3270−3279. DOI: 10.1210/JC.2015-1346. [24] Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial[J]. JAMA Oncol, 2018, 4(1): e173501. DOI: 10.1001/jamaoncol.2017.3501. [25] Siva S, Macmanus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review[J]. J Thorac Oncol, 2010, 5(7): 1091−1099. DOI: 10.1097/JTO.0b013e3181de7143. [26] Lee S, Eo W, Jeon H, et al. Prognostic significance of host-related biomarkers for survival in patients with advanced non-small cell lung cancer[J]. J Cancer, 2017, 8(15): 2974−2983. DOI: 10.7150/jca.20866. [27] Kim MJ, Kim SM, Lee EK, et al. Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer[J]. Endocr J, 2019, 66(7): 597−604. DOI: 10.1507/endocrj.EJ18-0488. [28] Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372(7): 621−630. DOI: 10.1056/NEJMoa1406470. [29] Lin YS, Wang C, Gao W, et al. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer[J]. Oncotarget, 2017, 8(26): 42252−42261. DOI: 10.18632/oncotarget.15036. [30] Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma[J]. Clin Oncol, 2010, 22(6): 464−468. DOI: 10.1016/j.clon.2010.03.014. [31] Spano JP, Vano Y, Vignot S, et al. GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma[J]. Med Oncol, 2012, 29(3): 1421−1428. DOI: 10.1007/s12032-011-0070-2. [32] Mould RC, Van Vloten JP, Auyeung AWK, et al. Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission[J]. Endocr Relat Cancer, 2017, 24(12): T311−T329. DOI: 10.1530/erc-17-0316. [33] Kim JH, Baek JH, Lim HK, et al. 2017 thyroid radiofrequency ablation guideline: Korean society of thyroid radiology[J]. Korean J Radiol, 2018, 19(4): 632−655. DOI: 10.3348/kjr.2018.19.4.632. [34] 曾萧贤, 张文文, 纪立秋, 等. 伴区域淋巴结或合并远处转移的放射性碘难治性分化型甲状腺癌125Ⅰ粒子植入治疗的疗效及安全性[J]. 现代肿瘤医学, 2020, 28(24): 4256−4261. DOI: 10.3969/j.issn.1672-4992.2020.24.009.
Zeng XX, Zhang WW, Ji LQ, et al. The efficacy and safety of 125I seeds implantation for the treatment of refractory differentiated thyroid carcinoma with regional lymph node or distant metastasis[J]. J Mod Oncol, 2020, 28(24): 4256−4261. DOI: 10.3969/j.issn.1672-4992.2020.24.009.
计量
- 文章访问数: 4132
- HTML全文浏览量: 2925
- PDF下载量: 22